<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22802" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fibrolamellar Hepatocellular Carcinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Melinda</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tomboc</surname>
            <given-names>Patrick J.</given-names>
          </name>
          <aff>WVUM Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Markovich</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Melinda Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Tomboc declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Markovich declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22802.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare&#x000a0;liver cancer that displays features that make it very different in its behavior and clinical findings from conventional hepatocellular carcinoma (HCC)[1]. FL-HCC accounts for less than 1% of all primary hepatic malignancies. Unlike conventional HCC, FL-HCC is more common in younger patients and has a significantly lower incidence. This activity describes the evaluation and treatment of FL-HCC and highlights the role of an interprofessional team in evaluating and treating patients with this malignancy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the common physical exam findings associated with FLC.</p></list-item><list-item><p>Identify the gold standard for the treatment of FLC.</p></list-item><list-item><p>Determine&#x000a0;the typical imaging findings associated with FLC.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration and coordination among the interprofessional team that can enhance patient care when deciding the treatment and management of patients with advanced disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22802&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22802">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22802.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare cancer of the liver. It displays features that make it very different in its behavior and clinical findings from conventional hepatocellular carcinoma (HCC).<xref ref-type="bibr" rid="article-22802.r1">[1]</xref>&#x000a0;FL-HCC accounts&#x000a0;for a negligible percentage of&#x000a0;primary liver cancers (1%). Patients affected by FL-HCC&#x000a0;are usually in a lower age group than&#x000a0;HCC.&#x000a0;The presenting complaints, blood tests, radiological evaluation, and treatment strategies differ from&#x000a0;HCC.&#x000a0;Prompt diagnosis and initiation of appropriate care plans play an important role in this disease entity, eventually affecting the outcome. This article aims at reviewing the salient features of FL-HCC, comparing it to HCC.<xref ref-type="bibr" rid="article-22802.r2">[2]</xref></p>
      </sec>
      <sec id="article-22802.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>No certain underlying trigger is detected in FL-HCC.&#x000a0;These patients do not have a history of cirrhosis or chronic liver disease. Less than 10% of patients with a diagnosis of FL-HCC have cirrhotic liver morphology.<xref ref-type="bibr" rid="article-22802.r3">[3]</xref>&#x000a0;This is very different from&#x000a0;underlying cirrhosis/liver fibrosis seen in patients diagnosed with conventional HCC.<xref ref-type="bibr" rid="article-22802.r2">[2]</xref></p>
      </sec>
      <sec id="article-22802.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Patients affected by FL-HCC most commonly are in the second or the third decade.<xref ref-type="bibr" rid="article-22802.r4">[4]</xref><xref ref-type="bibr" rid="article-22802.r5">[5]</xref>&#x000a0;In contrast, the patients with HCC are most commonly in an older age group, usually around the sixth decade. A very small percentage of primary liver cancer is attributed to Fl-HCC (1%). Although HCC appears to be more common in men, FL-HCC does not demonstrate any gender preference. More than half of the patients affected by FL-HCC are white, while greater than 80% of patients with HCC are white.<xref ref-type="bibr" rid="article-22802.r4">[4]</xref></p>
      </sec>
      <sec id="article-22802.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>At diagnosis, most FL-HCC masses are approximately slightly greater than 10cm. At the time of the histopathological examination, four-tenths of the patients have a positive margin and vascular invasion after resection. Metastasis to locoregional lymph nodes has been demonstrated in about half the patients. On examination, these tumors are usually large, single, yellow, with well-defined margins, and demonstrate features of rapid growth, outgrowing the blood supply, and having a central scar.</p>
      </sec>
      <sec id="article-22802.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Under microscopic examination, these tumors have big cells with eosinophilic cytoplasm, large central nuclei, and a central lamellated scar surrounding these large cells.<xref ref-type="bibr" rid="article-22802.r6">[6]</xref></p>
      </sec>
      <sec id="article-22802.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually present with symptoms and signs ranging from pain to a liver mass detected while evaluating some other clinical condition.<xref ref-type="bibr" rid="article-22802.r7">[7]</xref><xref ref-type="bibr" rid="article-22802.r8">[8]</xref>&#x000a0;The most common symptoms seem to be abdominal pain&#x000a0;or a palpable mass.&#x000a0;Symptoms commonly seen with a malignant process such as conventional HCC are not seen in&#x000a0;FL-HCC.<xref ref-type="bibr" rid="article-22802.r9">[9]</xref><xref ref-type="bibr" rid="article-22802.r10">[10]</xref>&#x000a0;Serum tumor markers do not have an important role in the evaluation or diagnosis of FL-HCC and are elevated in less than one-tenth of the patient population.<xref ref-type="bibr" rid="article-22802.r11">[11]</xref><xref ref-type="bibr" rid="article-22802.r7">[7]</xref></p>
      </sec>
      <sec id="article-22802.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Radiological evaluation appears to be the most useful evaluation tool. The most commonly used techniques include ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI).</p>
        <p>Sonographic features include a lobulated mass with varied echotexture. These findings are non-specific and may not help differentiate them from other hepatic neoplasms. The central scar is not easily discernible and, if present, can be seen as an area of increased echogenicity.<xref ref-type="bibr" rid="article-22802.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p>Computed Tomography usually shows a single tumor with well-demarcated margins, with most of these tumors showing decreased attenuation. Greater than 70% of the patients demonstrate a&#x000a0;calcified central scar. Liver mass CT protocol commonly involves different intravenously acquisitions at different time points following contrast administration to highlight features in the arterial, portal venous, and delayed phases. Greater than 80% of the patients demonstrate masses that have increased contrast avidity in the arterial phase, reflecting the high blood supply of these tumors. Almost half of these masses enhance similarly to the background liver in the venous phase, and about one-third of the tumors have higher contrast avidity. Almost two-thirds of these masses enhance similar to the background liver on the delayed phase and can be difficult to differentiate. The central fibrous scar in these masses can show contrast avidity in this later phase.<xref ref-type="bibr" rid="article-22802.r5">[5]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p>Magnetic resonance imaging shows a decreased signal on T1-weighted sequences in about two-thirds of the patients. The fibrous nature of the scar often demonstrates decreased signals on both T1 and T2 weighted sequences. The enhancement characteristics of the tumor and the central scar are similar to those described above on CT imaging.<xref ref-type="bibr" rid="article-22802.r13">[13]</xref>&#x000a0;Like many other malignant tumors, these also can show restricted diffusion with increased signal on diffusion-weighted imaging sequences (DWI).<xref ref-type="bibr" rid="article-22802.r14">[14]</xref>&#x000a0;In addition to the above findings, radiological evaluation plays an important role in detecting additional distant diseases that are not apparent otherwise.<xref ref-type="bibr" rid="article-22802.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22802.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Primary treatment of this tumor involves a treatment strategy that aims at a cure. When possible, complete resection is the preferred treatment, which appears to favor the outcome.<xref ref-type="bibr" rid="article-22802.r15">[15]</xref>&#x000a0;However, a high percentage of patients (greater than two-thirds) eventually show recurrent disease.<xref ref-type="bibr" rid="article-22802.r15">[15]</xref>&#x000a0;A good portion of these patients have locoregional diagnosis during the surgical treatment, and these additional sites of disease are also treated along with the primary tumor resection, which has shown to have a better prognostic value.<xref ref-type="bibr" rid="article-22802.r16">[16]</xref>&#x000a0;These tumors are often very aggressive in their behavior, and a failed surgical attempt at resection, the necessity of second surgical intervention, and finally, hepatic transplantation are often encountered. These additional interventions can hurt the outcome.<xref ref-type="bibr" rid="article-22802.r17">[17]</xref>&#x000a0;</p>
        <p>Chemotherapy has served as a treatment tool before and following surgical resection. Due to the limited incidence of FL-HCC, no RCT has elucidated the most efficacious chemotherapeutic regimen. Of note is that no neoadjuvant/adjuvant systemic therapies have yet been reported, showing an improved survival benefit in patients with resectable FL-HCC.<xref ref-type="bibr" rid="article-22802.r15">[15]</xref>&#x000a0;Chemotherapy with agents such as&#x000a0;gemcitabine, cisplatin, 5-fluorouracil, interferon, and oxaliplatin have to be utilized and have shown varying degrees of response.<xref ref-type="bibr" rid="article-22802.r18">[18]</xref><xref ref-type="bibr" rid="article-22802.r19">[19]</xref>&#x000a0;Combined treatment strategies, including surgery, chemotherapy, and radiation, have shown better outcomes.<xref ref-type="bibr" rid="article-22802.r20">[20]</xref>&#x000a0;Decreasing the mass size before surgical resection with percutaneous radioembolization has been studied.<xref ref-type="bibr" rid="article-22802.r21">[21]</xref>&#x000a0;A novel targeted therapy that has demonstrated efficacy in treating HCC, sorafenib, was evaluated retrospectively in FL-HCC, showing limited effectiveness.<xref ref-type="bibr" rid="article-22802.r19">[19]</xref>&#x000a0;Potential targets in the mTOR pathway and/or Aurora A kinase were recently identified. Currently, no controlled trials have evaluated these targets. There has been a favorable outcome in utilizing rapamycin (mTOR inhibitor) in an unresectable patient.<xref ref-type="bibr" rid="article-22802.r22">[22]</xref>&#x000a0;Checkpoint inhibition has shown reasonable efficacy in a Phase II study of advanced HCC.<xref ref-type="bibr" rid="article-22802.r23">[23]</xref>&#x000a0;Controlled trials evaluating checkpoint inhibitors in FL-HCC are lacking, and case reports to date are limited and unequivocal.<xref ref-type="bibr" rid="article-22802.r15">[15]</xref><xref ref-type="bibr" rid="article-22802.r19">[19]</xref></p>
      </sec>
      <sec id="article-22802.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of this disease includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Focal nodular hyperplasia</p>
          </list-item>
          <list-item>
            <p>Giant&#x000a0;cavernous hemangioma</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma (HCC)</p>
          </list-item>
        </list>
        <p>Imaging plays a crucial role in differentiating these lesions. Focal nodular hyperplasia demonstrates characteristics that follow the normal surrounding liver parenchyma on the portal venous and later delayed phase imaging. In the early arterial phase, it can show hyperenhancement which is usually uniform.<xref ref-type="bibr" rid="article-22802.r24">[24]</xref>&#x000a0;Calcification is not a common feature. The Hyperintense signal on T2-weighted&#x000a0;is seen in the central scar that can be seen in these masses and is attributed to biliary ductules as opposed to the scar related to FL-HCC&#x000a0;described above.<xref ref-type="bibr" rid="article-22802.r25">[25]</xref>&#x000a0;</p>
        <p>Cavernous hemangiomas follow the enhancement characteristics of blood vessels in all&#x000a0;3 phases. The classic pattern seen is a discontinuous and nodular enhancement pattern in the periphery of these masses in the early phases with subsequent contrast filling of the center.<xref ref-type="bibr" rid="article-22802.r26">[26]</xref></p>
        <p>Conventional HCC includes prompt enhancement in the arterial phase with a contrast washout in the delayed phases. These patients often have a cirrhotic liver, which is reflected in the imaging.</p>
      </sec>
      <sec id="article-22802.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Identifying a recurrent DNAJB1-PRKACA chimeric transcript in FLC by Honeyman et al initiated the growth in our ability to differentiate FL-HCC from conventional HCC. It may lead to insight into FL-HCC&#x02019;s pathogenesis.<xref ref-type="bibr" rid="article-22802.r27">[27]</xref> DNAJB1-PRKACA rearrangements are absent in conventional HCC and cholangiocellular tumors. DNAJB1-PRKACA and PRKACA rearrangement detection by break-apart fluorescence in situ hybridization (FISH) probe or polymerase chain reaction (PCR) provides both sensitive and specific elucidation in the context of primary hepatocellular neoplastic processes.<xref ref-type="bibr" rid="article-22802.r28">[28]</xref> Engelholm et al found that introducing the DNAJB1-PRKACA fusion gene into wild-type mice was sufficient to initiate hepatic tumors in mice with features consistent with human FLC.<xref ref-type="bibr" rid="article-22802.r29">[29]</xref></p>
      </sec>
      <sec id="article-22802.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Successful surgical treatment is associated with a better overall outcome. However, if there is a locoregional or distant disease, there is a negative impact on outcomes<xref ref-type="bibr" rid="article-22802.r30">[30]</xref><xref ref-type="bibr" rid="article-22802.r31">[31]</xref>. As expected, survival decreases as the number of disease site involvement increases.<xref ref-type="bibr" rid="article-22802.r32">[32]</xref>&#x000a0;If patients have findings of conventional HCC along with FL-HCC, which can rarely occur, there is a negative impact on prognosis.<xref ref-type="bibr" rid="article-22802.r6">[6]</xref> The&#x000a0;overall prognosis is superior to conventional HCC in the setting of underlying cirrhosis when compared to patients with a non-cirrhotic liver.<xref ref-type="bibr" rid="article-22802.r33">[33]</xref>&#x000a0;There is a statistically significant difference in the survival of patients diagnosed with FL-HCC compared to those with&#x000a0;conventional HCC. Factors correlated with improved outcomes include disease confined to the liver, completed removal of the tumor at surgery, and treatment with different modalities as described above.<xref ref-type="bibr" rid="article-22802.r1">[1]</xref><xref ref-type="bibr" rid="article-22802.r34">[34]</xref><xref ref-type="bibr" rid="article-22802.r20">[20]</xref></p>
      </sec>
      <sec id="article-22802.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Surgical complications are often encountered in these patients, especially those requiring complicated surgical treatment. Most patients affected with this disease are in a younger age group&#x000a0;with a disease extent that is often higher than other liver malignancies. This necessitates a complex and aggressive approach to treatment, resulting in a higher rate of surgical complications.</p>
      </sec>
      <sec id="article-22802.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education on the risks of this disease is essential as there is a high recurrence rate.&#x000a0;</p>
      </sec>
      <sec id="article-22802.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>These patients benefit from a treatment approach integrating different clinical teams familiar with treating complex malignancies with an evidence-based approach in a higher-level care center with the resources necessary to manage these patients.<xref ref-type="bibr" rid="article-22802.r35">[35]</xref><xref ref-type="bibr" rid="article-22802.r36">[36]</xref></p>
      </sec>
      <sec id="article-22802.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22802&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22802">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/fibrolamellar-hepatocellular-carcinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22802">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22802/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22802">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22802.s17">
        <title>References</title>
        <ref id="article-22802.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayo</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mavros</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.</article-title>
            <source>J Am Coll Surg</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>218</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-205</page-range>
            <pub-id pub-id-type="pmid">24315886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramakrishna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trehanpati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khosla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sarin</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence.</article-title>
            <source>Liver Cancer</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>3-4</issue>
            <fpage>367</fpage>
            <page-range>367-83</page-range>
            <pub-id pub-id-type="pmid">24400224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobel</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Metastasis suppressor genes.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1990</year>
            <month>Feb</month>
            <day>21</day>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>267</fpage>
            <page-range>267-76</page-range>
            <pub-id pub-id-type="pmid">2405170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Serag</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.</article-title>
            <source>Hepatology</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>798</fpage>
            <page-range>798-803</page-range>
            <pub-id pub-id-type="pmid">14999699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganeshan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szklaruk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaseb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kattan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elsayes</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>3340</fpage>
            <page-range>3340-3348</page-range>
            <pub-id pub-id-type="pmid">29948061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chagas</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alencar</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Tani</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Diniz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pugliese</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>Mde S</given-names>
              </name>
              <name>
                <surname>D'Albuquerque</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Carrilho</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases.</article-title>
            <source>Clinics (Sao Paulo)</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-13</page-range>
            <pub-id pub-id-type="pmid">26017653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahab</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El Hanafy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>El Nakeeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period).</article-title>
            <source>World J Gastrointest Surg</source>
            <year>2017</year>
            <month>Feb</month>
            <day>27</day>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-67</page-range>
            <pub-id pub-id-type="pmid">28289511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butte</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Waugh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meneses</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pruzzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carvallo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Redondo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de La Fuente</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Fibrolamellar liver carcinoma: report of two cases and review of the literature].</article-title>
            <source>Rev Med Chil</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>394</fpage>
            <page-range>394-400</page-range>
            <pub-id pub-id-type="pmid">19621182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma- report of a case.</article-title>
            <source>Chang Gung Med J</source>
            <year>2009</year>
            <season>May-Jun</season>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>336</fpage>
            <page-range>336-9</page-range>
            <pub-id pub-id-type="pmid">19527614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terzis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Haritanti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Economou</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma: a case report with distinct radiological features.</article-title>
            <source>J Gastrointest Cancer</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-5</page-range>
            <pub-id pub-id-type="pmid">19960280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Wahab</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El-Husseiny</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>El Hanafy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>El Shobary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver.</article-title>
            <source>Langenbecks Arch Surg</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>395</volume>
            <issue>6</issue>
            <fpage>625</fpage>
            <page-range>625-32</page-range>
            <pub-id pub-id-type="pmid">20358380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Siegelman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dachman</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma.</article-title>
            <source>Radiology</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>157</volume>
            <issue>3</issue>
            <fpage>583</fpage>
            <page-range>583-7</page-range>
            <pub-id pub-id-type="pmid">2997835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Federle</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Grazioli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Madariaga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nalesnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases.</article-title>
            <source>Radiology</source>
            <year>1999</year>
            <month>Nov</month>
            <volume>213</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-61</page-range>
            <pub-id pub-id-type="pmid">10551212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>McErlean</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>DeMatteo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Abou-Alfa</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>CT and MRI of primary and metastatic fibrolamellar carcinoma: a case series of 37 patients.</article-title>
            <source>Br J Radiol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>87</volume>
            <issue>1040</issue>
            <fpage>20140024</fpage>
            <pub-id pub-id-type="pmid">24896196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tella</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kommalapati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Borad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smoot</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mahipal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.</article-title>
            <source>J Gastrointest Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>554</fpage>
            <page-range>554-561</page-range>
            <pub-id pub-id-type="pmid">31183207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chagas</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Carrilho</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Cecconello</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of fibrolamellar hepatocellular carcinoma: an underestimated malignant tumor?</article-title>
            <source>Hepatobiliary Pancreat Dis Int</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>618</fpage>
            <page-range>618-21</page-range>
            <pub-id pub-id-type="pmid">25475864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemming</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sheiner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Greig</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Aggressive surgical management of fibrolamellar hepatocellular carcinoma.</article-title>
            <source>J Gastrointest Surg</source>
            <year>1997</year>
            <season>Jul-Aug</season>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>342</fpage>
            <page-range>342-6</page-range>
            <pub-id pub-id-type="pmid">9834368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Truant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boige</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ladrat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pruvot</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Hebbar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma.</article-title>
            <source>Case Rep Oncol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-72</page-range>
            <pub-id pub-id-type="pmid">22666208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mogler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Braren</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Alg&#x000fc;l</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ehmer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Progression after Immunotherapy for Fibrolamellar Carcinoma.</article-title>
            <source>Visc Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-42</page-range>
            <pub-id pub-id-type="pmid">31312648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maniaci</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Rolles</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Hackshaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Begent</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>617</fpage>
            <page-range>617-21</page-range>
            <pub-id pub-id-type="pmid">19144491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mafeld</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tiniakos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haugk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Manas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Littler</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection.</article-title>
            <source>Cardiovasc Intervent Radiol</source>
            <year>2018</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>816</fpage>
            <page-range>816-820</page-range>
            <pub-id pub-id-type="pmid">29468286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Choti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Klimstra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Torbenson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ferrell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>O'Reilly</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vallarapu</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stipa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Capanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dematteo</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Venook</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Abou-Alfa</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.</article-title>
            <source>Gastrointest Cancer Res</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">23505572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Edeline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cattan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verslype</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zagonel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fartoux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verset</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daniele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ebbinghaus</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <collab>KEYNOTE-224 investigators</collab>
            </person-group>
            <article-title>Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>940</fpage>
            <page-range>940-952</page-range>
            <pub-id pub-id-type="pmid">29875066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathieu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bruneton</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Drouillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pointreau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Vasile</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hepatic adenomas and focal nodular hyperplasia: dynamic CT study.</article-title>
            <source>Radiology</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>160</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">3520655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rummeny</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weissleder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sironi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Comptom</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wittenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrucci</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Central scars in primary liver tumors: MR features, specificity, and pathologic correlation.</article-title>
            <source>Radiology</source>
            <year>1989</year>
            <month>May</month>
            <volume>171</volume>
            <issue>2</issue>
            <fpage>323</fpage>
            <page-range>323-6</page-range>
            <pub-id pub-id-type="pmid">2539605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasanna</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Fredericks</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Winn</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Christman</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Best cases from the AFIP: giant cavernous hemangioma.</article-title>
            <source>Radiographics</source>
            <year>2010</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>1139</fpage>
            <page-range>1139-44</page-range>
            <pub-id pub-id-type="pmid">20631374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honeyman</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Robine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chiaroni-Clarke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Darcy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Gleason</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Teegan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Takacs</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Botero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belote</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Germer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Emde</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Vacic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhanot</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>LaQuaglia</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.</article-title>
            <source>Science</source>
            <year>2014</year>
            <month>Feb</month>
            <day>28</day>
            <volume>343</volume>
            <issue>6174</issue>
            <fpage>1010</fpage>
            <page-range>1010-4</page-range>
            <pub-id pub-id-type="pmid">24578576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dinh</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Vitucci</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Wauthier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Pitman</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Oikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Torbenson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sethupathy</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Mar</month>
            <day>17</day>
            <volume>7</volume>
            <fpage>44653</fpage>
            <pub-id pub-id-type="pmid">28304380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engelholm</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dagn&#x000e6;s-Hansen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Santoni-Rugiu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Niola</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;din</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates&#x000a0;That the Dnajb1-Prkaca Gene Fusion Is Sufficient&#x000a0;to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.</article-title>
            <source>Gastroenterology</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>153</volume>
            <issue>6</issue>
            <fpage>1662</fpage>
            <page-range>1662-1673.e10</page-range>
            <pub-id pub-id-type="pmid">28923495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darcy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Malek</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kobos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klimstra</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>DeMatteo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>La Quaglia</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in fibrolamellar hepatocellular carcinoma in young people.</article-title>
            <source>J Pediatr Surg</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-6</page-range>
            <pub-id pub-id-type="pmid">25598114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mavros</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hyder</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pawlik</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma.</article-title>
            <source>J Am Coll Surg</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>215</volume>
            <issue>6</issue>
            <fpage>820</fpage>
            <page-range>820-30</page-range>
            <pub-id pub-id-type="pmid">22981432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamashita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Kaseb</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Aloia</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Passot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raghav</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Shama</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.</article-title>
            <source>J Gastrointest Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1725</fpage>
            <page-range>1725-31</page-range>
            <pub-id pub-id-type="pmid">27456016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Njei</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Konjeti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Ditah</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.</article-title>
            <source>Gastrointest Cancer Res</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">24799971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaseb</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Shama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Nooka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassabo</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Aloia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abbruzzese</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Subbiah</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Janku</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Curley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.</article-title>
            <source>Oncology</source>
            <year>2013</year>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>197</fpage>
            <page-range>197-203</page-range>
            <pub-id pub-id-type="pmid">24051705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hijioka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwaya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuwahara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okuno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuraoka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Haneda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yatabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.</article-title>
            <source>Intern Med</source>
            <year>2018</year>
            <month>Dec</month>
            <day>15</day>
            <volume>57</volume>
            <issue>24</issue>
            <fpage>3537</fpage>
            <page-range>3537-3543</page-range>
            <pub-id pub-id-type="pmid">30101933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22802.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eser</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalgi&#x000e7;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akdemir</surname>
                <given-names>&#x000dc;&#x000d6;</given-names>
              </name>
              <name>
                <surname>O&#x0011f;uz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karadeniz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akyol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Demiro&#x0011f;ullari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boyuna&#x0011f;a</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Pinarli</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>e328</fpage>
            <page-range>e328-32</page-range>
            <pub-id pub-id-type="pmid">24608073</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
